There remain several unanswered questions regarding anti-LAG-3 treatment approach, including the impact of anti-LAG-3 and anti-PD-1 therapy in other settings, such as brain metastasis, adjuvant stage II/III melanoma, and rare melanoma subtypes, namely acral, mucosal, uveal, and desmoplastic melanoma. This evidence concerns the gene LAG3 and desmoplastic melanoma.